{"id":30570,"date":"2022-05-23T11:34:38","date_gmt":"2022-05-23T09:34:38","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=30570"},"modified":"2022-05-23T11:38:42","modified_gmt":"2022-05-23T09:38:42","slug":"30570","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/30570","title":{"rendered":"Antiepileptika-Konzentration in der Muttermilch f\u00fcr gestillte S\u00e4uglinge nicht beunruhigend [CME]"},"content":{"rendered":"<p>Im JAMA Neurology wurde 2020 die bisher umfangreichste Studie zu Plasmakonzentrationen ausgew\u00e4hlter Antiepileptika (AntiEpileptic Drugs = AED) bei S\u00e4uglingen ver\u00f6ffentlicht, die unter der Therapie ihrer an Epilepsie erkrankten M\u00fctter gestillt wurden . Die Autoren geh\u00f6ren der Arbeitsgruppe MONEAD (\u201eMaternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs\u201c) in den USA an, die Auswirkungen einer Antiepileptika-Exposition bei [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im JAMA Neurology wurde 2020 die bisher umfangreichste Studie zu Plasmakonzentrationen ausgew\u00e4hlter Antiepileptika (AntiEpileptic Drugs = AED) bei S\u00e4uglingen ver\u00f6ffentlicht, die unter der Therapie ihrer an Epilepsie erkrankten M\u00fctter gestillt wurden . Die Autoren geh\u00f6ren der Arbeitsgruppe MONEAD (\u201eMaternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs\u201c) in den USA an, die Auswirkungen einer Antiepileptika-Exposition bei [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[235,758,1373,237,1708,5675,5676,1709,5524,233,575,232],"class_list":["post-30570","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antiepileptika","tag-carbamazepin","tag-epilepsie","tag-lamotrigin","tag-levetiracetam","tag-monead-studie","tag-nead-studie","tag-oxcarbazepin","tag-stillen","tag-topiramat","tag-valproinsaeure","tag-zonisamid"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/30570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=30570"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/30570\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=30570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=30570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=30570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}